Navigation Links
Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
Date:4/20/2012

BALTIMORE, April 20, 2012 /PRNewswire/ -- Ameritox, the national leader in pain medication monitoring, today announced that it filed an amended complaint against San Diego-based Millennium Laboratories seeking damages, injunctive and other relief for false advertising, unfair competition, and unfair trade practices.  The Ameritox filing alleges that numerous Millennium Laboratories' business practices have resulted in violations of the Lanham Act, unfair competition in accordance with the Florida Deceptive and Unfair Trade Practices Act, California Business and Professions Code, New Hampshire Consumer Protection Act and national laws relating to unfair competition.

"It is tremendously harmful to physicians, their patients and the industry when a laboratory's business model, as alleged in this case against Millennium Laboratories, effectively flies in the face of ethical and legal business conduct and the healthcare provider's decision-making process," said Dr. Harry Leider, Chief Medical Officer at Ameritox. "These practices of providing financial incentives that mislead health professionals into believing that it is lawful for them to accept illegal inducements are a disservice to the public and the industry.  All companies must be held to the same high standards in providing patient-care services."

Federal Anti-Kickback Statute and numerous state anti-kickback statutes, including those of Arizona, Florida, California, New Hampshire and Texas, prohibit companies from providing financial inducements to health providers in order to induce the referral of business. These laws prohibit direct payments to physicians as an inducement for the referral of business, and prohibit other forms of kickbacks, such as the provision of equipment, supplies, tests, services, and other benefits to the health care provider at no cost or at below fair market value, as alleged against Millennium Laboratories. 

Ameritox, as the national leader in pain medication monitoring, believes it is important to provide a transparent exchange of business practices. The Company's programs are subject to OIG verification and Ameritox adheres to the highest standards in Federal and state policy.

Reporters have online access to complete documentation for this case -- Ameritox, LTD. V. Millennium Laboratories, Inc. in the UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION – via the public access service Public Access to Court Electronic Records (PACER).  Case number is 8:11-cv-00775-SCB-TBM.

About Ameritox

Ameritox is the nation's leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process — Rx Guardian(SM) — with Rx Guardian CD(SM), the only pain medication monitoring solution with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Medication monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on LinkedIn at linkedin.com/company/ameritox or on Facebook at facebook.com/ameritox.

© 2012 Ameritox Ltd. All rights reserved. AMERITOX, the AMERITOX logos, AMERITOX AUTOREMINDER, AMERITOX MEDICATION MONITORING SOLUTIONS, AMERITOX UNIVERSITY, PAIN MEDICATION MONITORING SOLUTIONS, POWERED BY YOUR NEED TO KNOW and PROTECT YOUR PATIENTS. PROTECT YOUR PRACTICE. RX GUARDIAN, RX GUARDIAN CD, and RX GUARDIAN AUTOREMINDER are trademarks of Ameritox.

For more information, contact:

Lon Wagner
Ameritox
Office: 336-387-7742
Lon.Wagner@ameritox.com

 


'/>"/>
SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
2. Ameritox® Continues to Advance Industry Leadership
3. Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients
4. Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion
5. Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy
6. Ameritox Commends Operation UNITE on Its Inaugural National Rx Drug Abuse Summit
7. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
8. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
9. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
10. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... A book about the self-discovery of one’s limitless creative power, “ Unleash Your ... give readers the courage they need to embrace their creativity and unleash it as ... my life to learn and create what I set my heart with no limits ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... "ProDrop 3D ... projects to the next level," said Christina Austin - CEO of Pixel Film Studios. ... Studios. With ProDrop 3D Abstract have the ability to generate and manipulate three-dimensional shapes ...
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical therapists ... physical therapy professional and every clinic has a duty to perform at the highest ... competitive industry is also essential. The solution that many physical therapy leaders turn to ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... “ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
Breaking Medicine News(10 mins):